Fate Therapeutics (NASDAQ:FATE – Get Free Report) and Grifols (NASDAQ:GRFS – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Fate Therapeutics and Grifols, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fate Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
| Grifols | 1 | 2 | 0 | 0 | 1.67 |
Fate Therapeutics presently has a consensus target price of $5.80, indicating a potential upside of 353.12%. Grifols has a consensus target price of $9.00, indicating a potential upside of 3.57%. Given Fate Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Fate Therapeutics is more favorable than Grifols.
Profitability
This table compares Fate Therapeutics and Grifols’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fate Therapeutics | -1,941.09% | -73.92% | -45.16% |
| Grifols | 5.54% | 6.21% | 2.39% |
Earnings and Valuation
This table compares Fate Therapeutics and Grifols”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fate Therapeutics | $4.75 million | 32.76 | -$136.32 million | ($1.03) | -1.24 |
| Grifols | $8.51 billion | 0.69 | $454.82 million | N/A | N/A |
Grifols has higher revenue and earnings than Fate Therapeutics.
Risk & Volatility
Fate Therapeutics has a beta of 2.65, suggesting that its stock price is 165% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.
Insider & Institutional Ownership
97.5% of Fate Therapeutics shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Fate Therapeutics beats Grifols on 7 of the 12 factors compared between the two stocks.
About Fate Therapeutics
Fate Therapeutics is a clinical-stage biotechnology company based in San Diego, California. It develops cellular immunotherapies using induced pluripotent stem cells (iPSCs), which can be engineered and used to produce populations of therapeutic cells. The company’s research focuses on off-the-shelf cell therapies, including natural killer (NK) cell and T-cell programs designed to target cancer. Its approach aims to create standardized therapies that do not require cells to be collected from each individual patient.
About Grifols
Grifols is a global healthcare company headquartered in Barcelona, Spain, focused on developing and producing plasma-derived medicines and other healthcare products. Founded in 1909, the company has expanded from its origins in laboratory services into a business spanning plasma collection, biopharmaceuticals, diagnostics and hospital solutions. Its biopharmaceutical business collects and processes human plasma to make medicines, including immunoglobulins, albumin and coagulation factors. Grifols also supplies diagnostic products and services for transfusion medicine and offers products used in hospitals and clinical laboratories.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
